Clinical characterization of Kidney Injury Molecule-1 (KIM-1) as a Biomarker in Renal Cell Carcinoma

肾损伤分子 1 (KIM-1) 作为肾细胞癌生物标志物的临床特征

• 批准号: 10541150
• 负责人: David McDermott
• 金额: $ 42.38万
• 依托单位: BETH ISRAEL DEACONESS MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-12-15 至 2026-11-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10541150
• 关键词: Address; Adjuvant; Adjuvant Study; Adjuvant Therapy; Angiogenesis Inhibitors; Angiomyolipoma; BAY 54-9085; Biological Markers; Blood; Blood Tests; Blood specimen; Case/Control Studies; Cessation of life; Clear Cell; Clinical; Clinical Trials; Cohort Studies; Collection; Cyst; Data; Diagnosis; Disease; Disease-Free Survival; Early Diagnosis; Eastern Cooperative Oncology Group; Enrollment; European; Excision; Future; Gene Expression Profile; Goals; Histologic; Immunoglobulins; Immunotherapy; Individual; Injury to Kidney; Integral Membrane Protein; International; International Agency for Research on Cancer; Kidney Neoplasms; Lead; Localized Disease; Measures; Medical center; Metastatic Renal Cell Cancer; Monitor; Mucins; Nephrectomy; Operative Surgical Procedures; Outcome; Papillary; Pathologic; Pathology; Patients; Phase; Phase III Clinical Trials; Plasma; Prediction of Response to Therapy; Prognosis; Prognostic Factor; Prognostic Marker; RNA; Randomized; Recurrence; Renal Cell Carcinoma; Renal Mass; Resected; Retrospective cohort; Risk; Risk Assessment; Sampling; Screening for cancer; T-Lymphocyte; Testing; Time; Validation; Work; blood-based biomarker; checkpoint therapy; circulating biomarkers; clinical prognostic; cohort; diagnostic biomarker; high risk; immune checkpoint; immunoregulation; improved; mortality; outcome prediction; participant enrollment; patient population; predict clinical outcome; prognostic; prospective; rat KIM-1 protein; relapse prediction; relapse risk; risk stratification; targeted treatment; treatment response; tumor

Project Summary While there are many treatment options for patients with metastatic RCC, it is still a deadly disease with considerable mortality. RCC can be much more effectively treated if it is detected early when it is amenable to surgery. To date there is no biomarker for RCC. Additionally, A specific and sensitive circulating biomarker could not only help detect this cancer earlier but could also aid in the diagnosis and monitoring of disease. This proposal seeks to test the utility of circulating kidney injury molecule-1/ T cell immunoglobulin mucin domain-1 (KIM-1/ TIM-1) as a blood test that can be used to follow patients with small renal masses and with the goal of safely avoiding or delaying surgery. We will also measure KIM1 in patients with resected RCC with the goal of identifying a high-risk patient population most likely to benefit from adjuvant therapy after nephrectomy for localized disease. This proposal will also test KIM-1 as a blood test that can help follow response to therapy for metastatic disease. To prepare for submission our team has spent considerable time and effort in identifying readily available patient samples to answer our questions. In this proposal we are poised and have samples available to address all of these questions. We hope that in the future, prospective trials will test KIM-1 in these settings but at this time, rigorous testing in these retrospective cohorts will provide the groundwork for these future studies.

项目摘要 虽然转移性RCC患者有许多治疗选择，但它仍然是一种致命的疾病， 相当大的死亡率。如果在适合治疗的早期发现，RCC可以更有效地治疗。 手术迄今为止，尚无RCC的生物标志物。此外，一种特异性和敏感性的循环生物标志物 不仅可以帮助早期发现这种癌症，还可以帮助诊断和监测疾病。 该提案旨在测试循环肾损伤分子-1/ T细胞免疫球蛋白粘蛋白的效用 结构域-1（KIM-1/ TIM-1）作为一种血液检测，可用于随访小肾脏肿块患者， 安全避免或延迟手术的目标。我们还将测量切除的RCC患者的KIM 1， 目标是确定最有可能从辅助治疗中获益的高危患者人群， 局限性疾病的肾切除术。这项提案还将测试KIM-1作为血液测试，可以帮助 跟踪对转移性疾病治疗的反应。为了准备提交，我们的团队 我们花费了大量的时间和精力来确定现成的患者样本，以回答我们的问题。在 我们准备好了这一提案，并提供了解决所有这些问题的样本。我们希望在 未来，前瞻性试验将在这些环境中测试KIM-1，但在这个时候，在这些环境中进行严格的测试， 回顾性队列将为这些未来研究提供基础。